05:31 PM EDT, 06/12/2025 (MT Newswires) -- Quince Therapeutics ( QNCX ) said Thursday that it priced a private placement of shares and warrants, which is expected to generate proceeds of up to $22 million.

The company said it entered into a securities purchase agreement with certain investors to sell its common shares and warrants, for about $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million, if the warrants are exercised in full for cash.

Quince said it plans to use the proceeds for working capital and general corporate purposes, including funding the ongoing enrollment of the phase 3 NEAT clinical trial in Ataxia-Telangiectasia.

The company said the offering proceeds, combined with its current cash, cash equivalents, and short-term investments, are expected to be sufficient for its operations into the second half of 2026.